Miscellaneous antifungal medications

Last updated: November 01, 2022

Miscellaneous antifungal medications

Emergency Medicine (Clinical Year)

Emergency Medicine (Clinical Year)

Advanced cardiac life support (ACLS): Clinical
Pneumothorax: Clinical
Traumatic brain injury: Clinical
Neck trauma: Clinical
Chest trauma: Clinical
Shock: Clinical
Abdominal trauma: Clinical
Burns: Clinical
Bites and stings: Clinical
Toxidromes: Clinical
Stroke: Clinical
Seizures: Clinical
Dizziness and vertigo: Clinical
Lower back pain: Clinical
Headaches: Clinical
Meningitis, encephalitis and brain abscesses: Clinical
Muscle weakness: Clinical
Advanced cardiac life support (ACLS): Clinical
Supraventricular arrhythmias: Pathology review
Ventricular arrhythmias: Pathology review
Heart blocks: Pathology review
Coronary artery disease: Clinical
Heart failure: Clinical
Syncope: Clinical
Pericardial disease: Clinical
Valvular heart disease: Clinical
Chest trauma: Clinical
Shock: Clinical
Peripheral vascular disease: Clinical
Leg ulcers: Clinical
Aortic aneurysms and dissections: Clinical
Sympatholytics: Alpha-2 agonists
Adrenergic antagonists: Presynaptic
Adrenergic antagonists: Alpha blockers
Adrenergic antagonists: Beta blockers
ACE inhibitors, ARBs and direct renin inhibitors
Loop diuretics
Thiazide and thiazide-like diuretics
Calcium channel blockers
cGMP mediated smooth muscle vasodilators
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Positive inotropic medications
Antiplatelet medications
Blistering skin disorders: Clinical
Bites and stings: Clinical
Burns: Clinical
Diabetes mellitus: Clinical
Hyperthyroidism: Clinical
Hypothyroidism and thyroiditis: Clinical
Parathyroid conditions and calcium imbalance: Clinical
Adrenal insufficiency: Clinical
Neck trauma: Clinical
Insulins
Mineralocorticoids and mineralocorticoid antagonists
Glucocorticoids
Abdominal pain: Clinical
Appendicitis: Clinical
Gastrointestinal bleeding: Clinical
Peptic ulcers and stomach cancer: Clinical
Inflammatory bowel disease: Clinical
Diverticular disease: Clinical
Gallbladder disorders: Clinical
Pancreatitis: Clinical
Cirrhosis: Clinical
Hernias: Clinical
Bowel obstruction: Clinical
Abdominal trauma: Clinical
Laxatives and cathartics
Antidiarrheals
Acid reducing medications
Blood products and transfusion: Clinical
Venous thromboembolism: Clinical
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Thrombolytics
Fever of unknown origin: Clinical
Infective endocarditis: Clinical
Pneumonia: Clinical
Tuberculosis: Pathology review
Diarrhea: Clinical
Urinary tract infections: Clinical
Meningitis, encephalitis and brain abscesses: Clinical
Protein synthesis inhibitors: Aminoglycosides
Antimetabolites: Sulfonamides and trimethoprim
Antituberculosis medications
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Cell wall synthesis inhibitors: Penicillins
Miscellaneous protein synthesis inhibitors
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Herpesvirus medications
Azoles
Echinocandins
Miscellaneous antifungal medications
Anthelmintic medications
Antimalarials
Anti-mite and louse medications
Hypernatremia: Clinical
Hyponatremia: Clinical
Hyperkalemia: Clinical
Hypokalemia: Clinical
Metabolic and respiratory acidosis: Clinical
Metabolic and respiratory alkalosis: Clinical
Toxidromes: Clinical
Medication overdoses and toxicities: Pathology review
Acute kidney injury: Clinical
Kidney stones: Clinical
Stroke: Clinical
Seizures: Clinical
Headaches: Clinical
Traumatic brain injury: Clinical
Lower back pain: Clinical
Spinal cord disorders: Pathology review
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Nonbenzodiazepine anticonvulsants
Migraine medications
Osmotic diuretics
Opioid agonists, mixed agonist-antagonists and partial agonists
Opioid antagonists
Asthma: Clinical
Chronic obstructive pulmonary disease (COPD): Clinical
Acute respiratory distress syndrome: Clinical
Pleural effusion: Clinical
Pneumothorax: Clinical
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Joint pain: Clinical
Hypertensive disorders of pregnancy: Clinical
Antepartum hemorrhage: Clinical
Premature rupture of membranes: Clinical
Postpartum hemorrhage: Clinical
Pediatric infectious rashes: Clinical
Pediatric bone and joint infections: Clinical
Skin and soft tissue infections: Clinical
Substance misuse and addiction: Clinical
Drug misuse, intoxication and withdrawal: Hallucinogens: Pathology review
Psychiatric emergencies: Pathology review

Transcript

Watch video only

Antifungal agents are a class of medications used to treat mycoses, or fungal infections.

Mycoses can be superficial, meaning they are localized on the skin, or develop into systemic infections in immunodeficient patients.

Antifungals work either through fungistatic action, meaning that they inhibit fungal growth, or through fungicidal action, meaning they kill the fungi.

Now, antifungals include the azole family and a novel class of medications, echinocandins; but there are also many other antifungals with similar or different mechanisms that we’ll talk about in this video.

Okay, most fungal cells have a tough outer cell wall and an inner cell membrane.

The cell membrane is mostly made of phospholipids with some sterol or modified steroid molecules mixed in.

Humans have cholesterol, while fungi have ergosterol. Both sterol molecules help keep the cell membrane stable at a wide range of temperatures.

Now, the precursor to both molecules is lanosterol.

The precursor of lanosterol is squalene.

The conversion of squalene to lanosterol is catalyzed by an enzyme called squalene epoxidase.

Fungi have a cytochrome p450 enzyme called fourteen-alpha-demethylase in their mitochondria and endoplasmic reticulums, which converts lanosterol to ergosterol.

Without ergosterol, the structure of the cell membrane will be disrupted.

This will cause membrane-bound proteins, like ion channels, to stop working properly.

The membrane also becomes fragile, which eventually leads to inhibition of fungal growth.

Okay, let’s start with polyenes, which are naturally-derived antifungal antibiotics that alter cell membrane permeability.

They include amphotericin, also called amphotericin B, and nystatin.

Polyenes have both hydrophilic, meaning they love water, and lipophilic, meaning they love fats, characteristics.

They bind to ergosterol, and the hydrophilic core causes the formation of artificial pores in the cell membrane, thereby creating a leaky membrane.

This causes significant changes in ion balance including the loss of intracellular potassium.

Depending on their concentration, polyenes are either fungistatic or fungicidal.

Now, amphotericin B is one of the most important medications for the treatment of systemic mycoses. It’s used to fight systemic infections caused by Aspergillus, Blastomyces, Candida albicans, Cryptococcus, Histoplasma, and Mucor, either alone or in combination with other drugs.

However, nowadays several azoles and echinocandins are proving to be just as effective in specific systemic mycoses as amphotericin B is, with less risk of toxicity.

Amphotericin B is also used in the treatment of visceral Leishmaniasis, caused by protozoan parasites of the genus Leishmania, that presents with fever, weight loss, fatigue, anemia, and substantial swelling of the liver and spleen.

It’s usually given by slow intravenous infusion, as it is poorly absorbed by the gastrointestinal tract.

In fungal meningitis intrathecal administration, meaning injection into the spinal canal, or into the subarachnoid space, has been used, since the drug is widely distributed to all tissues except the central nervous system, or CNS, when administered intravenously.

It can also be administered locally in the treatment of mycotic corneal ulcers and keratitis.

Amphotericin is mainly eliminated via hepatic metabolism, while a small fraction is excreted through the kidneys.

Alright, now common side effects are infusion-related and include fever, chills, muscle spasms, vomiting, headache, and in more severely affected individuals, hypotension and anaphylactoid reactions.

The most serious side effect is renal toxicity which is dose dependent and can be decreased with hydration.

Anemia may also occur due to reduction of erythropoietin production from the kidneys.

Amphotericin decreases glomerular filtration rate in the majority of the patients, which improves after treatment stops, and causes renal tubular acidosis with loss of magnesium and potassium.

This can lead to hypokalemia and hypomagnesemia which often requires subsequent potassium and magnesium supplementation.

The electrolyte imbalance can cause arrythmias.

Other side effects include impaired hepatic function and intrathecal administration may cause seizures and neurotoxicity.

Next, nystatin is an antifungal agent that is only effective in the treatment of Candida infections of the skin, mucous membranes and gastrointestinal tract.

It’s used either topically for superficial infections or orally to fight gastrointestinal fungi in patients with impaired defense mechanisms.

Side effects for the oral form include gastrointestinal disturbances like nausea, abdominal pain, vomiting, and diarrhea.

Both the oral and the topical form can cause hypersensitivity reactions such as Stevens-Johnson syndrome, which is a dangerous immune-mediated condition that affects the skin and mucous membranes such as the mouth and genitals, and also rashes, itching, and burning.

Moving on to terbinafine, which is a synthetic antifungal antibiotic that alters cell membrane permeability.

Key Takeaways

There are a few different types of antifungal medications, but they all work in similar ways. Most of them work by disrupting the formation of the fungal cell wall, which eventually kills the fungus. Some common antifungal medications include azoles (such as fluconazole and itraconazole), polyenes (such as amphotericin B and nystatin), and echinocandins (such as caspofungin and anidulafungin).

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "The antifungal pipeline: a reality check" Nature Reviews Drug Discovery (2017)
  5. "Onychomycosis" Journal of the American Academy of Dermatology (2019)
  6. "New Antifungal Agents and New Formulations Against Dermatophytes" Mycopathologia (2016)